Upshaw–Schulman syndrome

Upshaw–Schulman syndrome
Blood smear under the microscope with typical schistocytes in TTP marked in blue – H&E stain
Classification and external resources
Specialty rheumatology
ICD-10 M31.1 (ILDS M31.110)
ICD-9-CM 446.6
OMIM 274150
DiseasesDB 13052
MedlinePlus 000552
eMedicine emerg/579 neuro/499 med/2265
MeSH D011697

Upshaw–Schulman syndrome (USS) is the recessively inherited form of thrombotic thrombocytopenic purpura (TTP), a rare and complex blood coagulation disease. USS is caused by the absence of the ADAMTS13 protease resulting in the persistence of unusually large von Willebrand factor multimers (ULVWF), causing episodes of acute thrombotic microangiopathy with disseminated multiple small vessel obstructions.[1][2] These obstructions deprive downstream tissues from blood and oxygen, which can result in tissue damage and death. The presentation of an acute USS episode is variable but usually associated with thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytes on the peripheral blood smear,[3] fever and signs of ischemic organ damage in the brain, kidney and heart.

Epidemiology

The incidence of acute TTP in adults is around 1.7–4.5 per million and year.[4][5] These cases are nearly all due to the autoimmune form of TTP, where autoantibodies inhibit ADAMTS13 activity.[1][6] The prevalence of USS has not yet been determined but is assumed to constitute less than 5% of all acute TTP cases. The syndrome's inheritance is autosomal recessive, and is more often caused by compound heterozygous than homozygous mutations.[7] The age of onset is variable and can be from neonatal age up to the 5th–6th decade.[1] The risk of relapses differs between affected individuals.[1][6] Minimization of the burden of disease can be reached by early diagnosis and initiation of prophylaxis if required.[2]

Aetiology

Genetic mutations

The ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif 13) gene is located on chromosome 9q34 and encoding 29 exons.[8] The ADAMTS13 protease consists of 1427 amino acids and has several protein domains:[1][8]

Disease causing mutations in ADAMTS13, which can be found in all ADAMTS13 protease domains.[10] result predominantly in impaired ADAMTS13 secretion with or without decreased ADAMTS13 protease activity.[9] More than 120 disease causing mutations and numerous single nucleotide polymorphisms (SNP) are known today.[13][14] Residual ADAMTS13 activity has been observed with certain mutations and seems to be associated with a later disease-onset.[13] It has been postulated that some SNPs interact with each other and may amplify or reduce overall ADAMTS13 activity.[8][9]

ADAMTS13 function and pathogenesis

The ADAMTS protease family contains enzymes that process collagen, cleave inter-cellular matrix, inhibit angiogenesis and blood coagulation. ADAMTS13 belongs to the zinc metalloproteases, and is mainly expressed in liver stellate cells and endothelial cells, but was also found in other cell types, such as platelets, podocytes in the kidney and several brain cells.[10][15][16] The only known role of the ADAMTS13 protease is to cleave VWF multimers.[17] The plasma half-life of administered ADAMTS13 in USS patients is around 2–4 days, whereas the protective effects seems to last longer.[18][19]

Usually USS patients have a severely deficient ADAMTS13 activity of <10% of the normal.[6] In this low range there may be residual ADAMTS13 activity, depending on the underlying mutations.[8][9][13]

In USS severe ADAMTS13 deficiency is often not enough to induce a (first) acute TTP episode. It primarily occurs when an additional (environmental) trigger is present.[1][8][10] Recognized triggers are infections (including mild flu-like upper airway infections), pregnancy,[20] heavy alcohol intake[18] or certain drugs.[1][6] In these situations, VWF is released from its storage organells, e.g. Weibel–Palade bodies and granules of platelets. Increased VWF levels in the circulation are leading to a higher demand of ADAMTS13, which is lacking in USS, and can bring forward a TTP episode.[3][11]

Pathology

After secretion, ADAMTS13 is either bound to the endothelial surface or free in the blood stream.[3] The heightened shear stress in small- and microvessels alters the 3D-structure of VWF from the contracted globular form to its linear form.[10] The linear VWF has now its active binding sites exposed, that are important to start blood coagulation.[10] These sites bind platelets and blood vessel lesions by interlinking the stretched VWF with one another – a blood clot is formed.[10] In its uncut form, (ultra large) VWF's heightened stickiness and interlinking causes spontaneous platelet binding and blood clotting.[10] The linear VWF exposes the A2 domain, so that in the presence of enough ADAMTS13 activity it gets cut to its normal size.[3] VWF in the normal length loses its heightened stickiness and spontaneous crosslinking activity to only form blood clots when needed.[3]

Symptoms

The presentation of TTP is variable. The initial symptoms, which force the patient to medical care, are often the consequence of lower platelet counts like purpura (present in 90% of patients), ecchymosis and hematoma.[21] Patients may also report signs and symptoms as a result of (microangiopathic) hemolytic anemia, such as (dark) beer-brown urine, (mild) jaundice, fatigue and pallor. Cerebral symptoms of various degree are present in many patients, including headache, paresis, speech disorder, visual problems, seizures and disturbance of consciousness up to coma. The symptoms can fluctuate so that they may only be temporarily present but may reappear again later in the TTP episode. Other unspecific symptoms are general malaise, abdominal, joint and muscle pain. Severe manifestations of heart or lung involvements are rare, although affections are not seldom measurable (e.g. ECG-changes).[22]

Diagnosis

A diagnosis of TTP is based on the clinical symptoms with the concomitant presence of thrombocytopenia (platelet count below 100×109/L) and microangiopathic hemolytic anemia with schistocytes on the blood smear, a negative direct antiglobulin test (coombs test), elevated levels of hemolysis markers (e.g. total bilirubin, LDH, free hemoglobin and an unmeasurable haptoglobin), after exclusion of any other apparent cause.[1][2]

USS can present similar to the following diseases which have to be excluded: fulminant infections, disseminated intravascular coagulation, autoimmune hemolytic anemia, Evans syndrome, the typical and atypical form of hemolytic uremic syndrome (HUS), HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, pre-eclampsia, heparin-induced thrombocytopenia (HIT), cancer that is often accompanied with metastasis, kidney injury, antiphospholipid antibody syndrome and side effects from hematopoietic stem cell transplantation.[1][2]

Of note is that pregnancy associated affections like pre-eclampsia, eclampsia and HELLP syndrome can overlap in their presentation as pregnancy can trigger TTP episodes.[23]

Patients with fulminant infections, disseminated intravascular coagulation, HELLP syndrome, pancreatitis, liver disease and other active inflammatory conditions may have reduced ADAMTS13 activity but almost never a relevant severe ADAMTS13 deficiency <10% of the normal.[2][24]

A severe ADAMTS13 deficiency below 5% or <10% of the normal (depending on the definitions)[1][25] is highly specific for the diagnosis of TTP.[18][26] ADAMTS13 activity assays are based on the direct or indirect measurement of VWF-cleavage products. Its activity should be measured in blood samples taken before therapy has started, to prevent false high ADAMTS13 activity.[2] If a severe ADAMTS13 deficiency is present an ADAMTS13 inhibitor assay is needed to distinguish between the acquired, autoantibody-mediated and the congenital form of TTP (USS).[1] The presence of antibodies can be tested by ELISA or functional inhibitor assays. The level of ADAMTS13 inhibitor may be fluctuating over the course of disease and depends on free circulatory antibodies, therefore an onetime negative test result does not always exclude the presence of ADAMTS13 inhibitors and thereby an autoimmune origin of TTP.[2] A severe ADAMTS13 deficiency in the absence of an inhibitor, confirmed on a second time point in a healthy episode of a possible USS patient, usually sets the trigger to perform a molecular analysis of the ADAMTS13 gene to confirm a mutation. In unclear cases a plasma infusion trial can be done, showing an USS in the absence of anti-ADAMTS13-antibodies a full recovery of infused plasma-ADAMTS13 activity as well as a plasma half-life of infused ADAMTS13 activity of 2–4 days. A deficiency of ADAMTS13 activity in first-degree relatives is also a very strong indicator for an Upshaw-Schulman Syndrome.[1][2][6]

Therapy

The therapy of an acute TTP episode has to be started as early as possible.[1][2] The standard treatment is the daily replacement of the missing ADAMTS13 protease in form of plasma infusions or in more severe episodes by plasma exchange. In the latter the patients plasma is replaced by donated plasma.[27] The most common sources of ADAMTS13 is platelet-poor fresh frozen plasma (FFP)[3] or solvent-detergent plasma.

The benefit of plasma exchange compared to plasma infusions alone may result from the additional removal of ULVWF.[1][27] In general both plasma therapies are well tolerated, several mostly minor complications may be observed.[2][27] The number of infusion/exchange sessions needed to overcome a TTP episode are variable but usually take less than a week in USS.[1][6] The intensive plasma-therapy is generally stopped when platelet count increases to normal levels and is stable over several days.[1][2]

Preventive therapy

Not all affected patients seem to need a regular preventive plasma infusion therapy, especially as some reach longterm remission without it.[28] Regular plasma infusions are necessary in patients with frequent relapses and in general situations with increased risk to develop an acute episode (as seen above) such as pregnancy. Plasma infusions are given usually every two to three weeks to prevent acute episodes of USS[18] but are often individually adapted.

Outlook

Several therapy developments for TTP emerged during recent years. Artificially produced ADAMTS13 has been used in mice[29] and testing in humans has been announced. Another drug in development is targeting VWF and its binding sites, thereby reducing VWF-platelet interaction, especially on ULVWF during a TTP episode.[30] Among several (multi-)national data bases a world-wide project has been launched to diagnose USS patients and collect information about them to gain new insights into this rare disease with the goal to optimize patient care.[31]

History

M.D. Jefferson D. Upshaw

TTP was first recognized as a disease in 1947 and the name was given according to symptoms and underlying pathophysiology which differed from the already known immune thrombocytopenia.[18] Schulman reported a case of TTP in 1960[1] and Upshaw published a paper in 1978 about relapsing TTP in a patient whom he had followed for 11 years.[32] In his report Upshaw noted the similarities with the reported case by Schulman and hypothesized that the two cases had similar causes – a missing plasma factor.[1][32] One year later the disease was named Upshaw-Schulmann Syndrome.[33] In 1996 the VWF-cleaving protease was discovered and in the following year found to be the major issue in TTP's pathogenesis.[17][34][35] 2001 through different strategies the VWF-cleaving protease was identified as ADAMTS13, the gene was mapped to chromosome 9q34 and the first USS-causing mutations were identified.[1][19]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 J. E. Sadler, von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura, American Society of Hematology 2008, 112:11-18
  2. 1 2 3 4 5 6 7 8 9 10 11 R. Sarode, N. Bandarenko, M.E. Brecher, J.E. Kiss, M.B. Marques, Z.M. Szczepiorkowski, and J.L. Winters, Thrombotic thrombocytopenic purpura, 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research, journal of Clinical Apheresis J. Clin. Apheresis. doi: 10.1002/jca.21302 29:148-167 (2014)
  3. 1 2 3 4 5 6 J.L. Moake, M.D.: MECAHNISMS OF DISEASE: THROMBOTIC MICROANGIOPATHIES, in the New England Journal of Medicine August 22, 2002, vol. 347, p. 589–600
  4. ↑ D.R. Terell, L.A. Williams, S.K. Vesely, B. Lämmle, J.A.K. Hovinga, J.N. George, The incidence of thrombotic thrombocytopenic purpura – hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency, journal of Thrombosis and Haemostasis July 2005 P. 1432–1436
  5. ↑ JA. Reese, DS. Muthurajah, JA. Kremer Hovinga, SK. Vesely, DR. Terrell, JN. George, Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features, - Pediatr Blood Cancer. 2013 Oct;60(10), P. 1–7
  6. 1 2 3 4 5 6 7 J.T.B. Crawley, M.A. Scully, Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies, American Society of Hematology, 2013, P. 292–299
  7. ↑ R. Schneppheim, J.A. Kremer Hovinga, T. Becker, U. Budde, D. Karpman, W. Brockhaus, I. Harchovinová, B. Korczowski, F. Oyen, S. Rittich, J. von Rosen, G.E. Tjonnfjord, J.E. Pimanda, T.F. Wienker, B. Lämmle, A common origin of the 4143insA ADAMtS13 mutation, Thrombosis and Hemostasis, July 2006. P. 3-6
  8. 1 2 3 4 5 R.S. Camilleri, H. Cohen, I.J. Mackie, M. Scully, R.D. Starke, J.T.B. Crawley, D.A. Lane, S.J. Machin, Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura, journal oft Thrombosis and Haemmostasis, 2008, p.331-338
  9. 1 2 3 4 5 6 7 B. Plaimauer, J. Fuhrmann, G. Mohr, W. Wernhart, K. Bruno, S. Ferrari, Ch. Konetschny, G. Antoine, M. Rieger, F. Scheiflinger, Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and missense mutation, Blood, January 1, 2006, Vol 107, p. 118–124
  10. 1 2 3 4 5 6 7 8 9 10 S. Lancellotti, M. Bassao, R. De Cristofaro. Proteolytic Processing of Von Willebrand Factor by ADAMTS13 and Leukocyte Proteases. Mediterranean Journal of Hematology and Infectious Diseases, September 2, 2013, p. Vol. 5 No. 1 ISSN 2035-3006
  11. 1 2 3 4 M. Galbusera, M. Noris, G. Remuzzi: Thrombotoic thrombocytopenic Purpura – Then and Now. Seminars in Thrombosis and Hemostasis by Thieme Medical Publishers 2006, 32(2) 081-089
  12. ↑ Z. Zhou, H. Xeh, H. Jing, C. Wang, Z. Tao, H. Choi, K. Aboulfatova, R. Li, J. Dong: Cystein residues in CUB-1 domain are critical for ADAMTS13 secretion and stability, Schattauer Verlag 2011, 105(1): 21-30
  13. 1 2 3 LA. Lotta, HM. Wu, IJ. Mackie, M. Noris, A. Veyradier, MA. Scully, G. Remuzzi, P. Coppo, R. Liesner, R. Donadelli, C. Loirat, RA. Gibbs, A. Horne, S. Yang, I. Garagiola, KM. Musallam, F. Peyvandi. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura, Blood, July 12, 2012, 120(2)
  14. ↑ LA. Lotta, I. Garagiola, R. Palla, A. Cairo, F. Peyvandi, ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010 Jan;31(1) 11-9
  15. ↑ M. Manea, A. Kristoffersson, R. Schneppenheim, M.A. Saleem, P.W. Mathieson, M. Mörgelin, P. Björk, L. Holmberg, D. Karpman, Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura, british journal of haematology september 2007 volume 138 issue 5 p. 651-662
  16. ↑ R. Tauchi, S. Imagama, T. Ohgomori, T. Natori, R. Shinjo, N. Ishiguro, K. Kadomatsu, ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury, Elvesier Neuroscience Letters, March 2012 Volume 517 Issue 1 p. 1-6
  17. 1 2 M. Furlan, R. Robles, B. Lämmle, Partial Purification and Characterization of a Protease From Human Plasma Cleaving von Willebrand Factor to Fragments Produced by In Vivo Proteolysis, Blood May 15, 1996, Vol. 87, p.4223-4234
  18. 1 2 3 4 5 J.A. Kremer Hovinga, B. Lämmle, Role of ADAMTS13 in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura, hematology Vol. 2012 no1 p.610-616
  19. 1 2 M. Furlan, R. Robles, B. Morselli, P. Sandoz, B. Lämmle, Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura, Schattauer Verlag, Stuttgart 1999, p. 8–13
  20. ↑ Y. Jiang, J.J. Mclntosh, J.A. Reese, C.C. Deford, J.A. Kremer Hovinga, B. Lämmle, D.R. Terrel, S.K. Vessely, E.J. Knudtson, J.N. George, pregnancy outcomes following recovery form acquired thrombotic thrombocytopenic purpura, american society of hematology, March 13, 2014, Vol123 No.11, p.1674-1680
  21. ↑ J.N. George, Q. Chen, C.C. Deford, Z. Al-Nouri, "Ten Patient Stories Illustrating the Extraordinarily Diverse Clinical Features of Patients With Thrombotic Thrombocyytopenic Purpura and Sever ADAMTS13 Deficiency", Journal of Clinical Apheresis, 2012, p. 302–311
  22. ↑ M. Galbusera, M. Noris, G. Remuzzi, Thrombotoic thrombocytopenic Purpura – Then and Now, Seminars in Thrombosis and Hemostasis by Thieme Medical Publishers, 2006, p. 81–89
  23. ↑ E. Yamashita, H. Okada, H. Yorioka, S. Fujita, K. Nishi, Y. Komiyama, H. Kanzaki: Successful management of pregnancy-associated thrombotic thrombocytopenic purpura by monitoring ADAMTS13 activity. Journal of Obstetrics and Gynaecology Research, March 2012, Vol. 38, p.567-569
  24. ↑ M. Uemura, Y. Fujimura, S. Ko, M. Matsumoto, Y. Nakajima, H. Fukui, Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis, International Journal of Hepatology, February 25, 2011, p. 1–12
  25. ↑ JN. George, ZL. Al-Nouri, Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes, Hematology Am Soc Hematol Educ Program, 2012, p. 604-609
  26. ↑ A. Tripodi, F. Peyvandi, V. Chantarangkul, R. Palla, A. Afrasiabi, M.T. Canciani, D.W. Chung, S. Ferrari, Y. Fujimura, M. Karimi, K. Kokame, J.A. Kremer Hovinga, B. Lämmle, S.F. De Meyer, B. Plaimauer, K. Vanhoorelbeke, K. Varadi, P.M. Mannucci, Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, Vol. 60, p.1676-1682
  27. 1 2 3 G.A. Rock, Ph.D., M.D., K.H. Shumak, M.D., N.A. Buskard, M.D., Victor S. Blanchette, M.D., J.G. Kelton, M.D., R.C. Nair, Ph.D., R.A. Spasoff, M.D., and the Canadian Apheresis Study Group: COMPARISON OF PLASMA EXCHANGE WITH PLASMA INFUSION IN THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA. In the New England Journal of Medicine Edition August 8, 1991, Vol. 325 No. 6, p. 393–397
  28. ↑ P. Knöbl, Inherited and Acquired Thrombotic Thrombocytopenic Purpura (TTP) in Adults, Semin Thromb Hemost 2014, p. 493–502
  29. ↑ A. Schiviz, K. Wuersch, C. Piskernik, B. Dietrich, W. Hoellriegl, H. Rottensteiner, F. Scheiflinger, H.P. Schwarz, E. Muchitsch, A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13, american society of hematology, 2012, p. 6128-6135
  30. ↑ J-B. Holz, The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thormbotic thrombocytopenic purpura, Elsevier Science Direct 2012, p. 343-346
  31. ↑ M. Mansouri Taleghani, A-s. von Krogh, Y. Fujimura, J.N. George, I. Hrachovinova, P.N. Knöbl, P. Quist-Paulsen, R. Schneppenhiem, B. Lämmle, J.A. Kremer Hovinga: Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry, Hamostaseologie. 2013 May 29;33(2)
  32. 1 2 J.D. Upshaw, Jr., M.D.: CONGENITAL DEFICIENCY OF A FACTOR IN NORMAL PLASMA THAT REVERSES MICROANGIOPATHIC HEOLYSIS AND THROMBOCYTOPENIA, In the New England Journal of Medicine Edition, June 15, 1978, p. 1350-1352
  33. ↑ S. Rennard, S. Abe, Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome), New England Journal of Medicine, February 15, 1979, 300(7):368
  34. ↑ H. Tsai, Physiologic Cleavage of von Willebrand Factor by a Plasma Protease Is Dependent on Its Conformation and Requires Calcium Ion, Blood, May 15, 1996, Vol 87, p. 4235-4244
  35. ↑ M. Furlan, R. Robles, M. Solenthaler, M. Wassmer, P. Sandoz, B. Lämmle, Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura, Blood, May 1, 1997, 89(9):3097-103
This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.